CRISPR (CRSP) Gains Analyst Support on Sales Momentum and Pipeline Expansion

CRISPR Therapeutics AG (NASDAQ:CRSP) is one of the best emerging technology stocks to buy right now. On September 3, Bank of America Securities analyst Alec Stranahan reiterated a Buy rating on CRISPR Therapeutics AG (NASDAQ:CRSP) with an unchanged price target of $78.

The rating comes as the company continues to advance its CRISPR/Cas9 gene-editing platform, a breakthrough technology for gene editing that enables precise changes to DNA sequences and directly corrects faulty genes. With a pipeline that spans treatments for blood disorders, cancer, and rare genetic diseases, CRISPR Therapeutics AG (NASDAQ:CRSP) is positioning itself at the forefront of one of the most disruptive innovations in biotechnology.

While still in the early stages of commercialization, the technology’s potential to reshape the treatment landscape is becoming increasingly clear.

That view had also been echoed earlier by H.C. Wainwright analyst Mitchell Kapoor. On August 7, the analyst reiterated a Buy rating and lifted his price target to $80 from $65, citing a 114% quarter-over-quarter increase in CASGEVY sales during Q2 2025.

He pointed to accelerating patient adoption, bolstered by the expansion of 75 authorized treatment centers, as well as CRISPR Therapeutics AG’s (NASDAQ:CRSP) strong cash position that extends its operating runway into 2027.

Kapoor also added projections for CTX310 to his model, estimating peak revenue potential of $4 billion, which further strengthens the long-term growth story.

We can safely say that the combination of analyst conviction, rising sales momentum, and a robust pipeline suggests that CRISPR is beginning to shift from a promise to delivery, offering investors exposure to one of the most compelling stories in emerging biotechnology.

CRISPR Therapeutics AG (NASDAQ:CRSP) is a gene-editing company that is developing transformative therapies using its proprietary CRISPR/Cas9 platform. Its pipeline spans treatments for hemoglobinopathies, oncology, regenerative medicine, and rare genetic diseases.

While we acknowledge the potential of CRSP as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: Best Stocks For Day Trading: 12 Stock Picks and 15 Best Multibagger Stocks to Invest in Right Now.

Disclosure: None. This article is originally published at Insider Monkey.